EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of C1orf50 in breast cancer progression and prognosis

Yusuke Otani, Atsushi Tanaka, Masaki Maekawa, Tirso Peña, Anna Rogachevskaya, Teruhiko Ando, Takuto Itano, Haruyoshi Katayama, Eiji Nakata, Toshifumi Ozaki, Shinichi Toyooka, Hiroyoshi Doihara und 2 weitere

Breast Cancer · 2025

DOI: 10.1007/s12282-024-01653-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Yusuke Otani und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan, Agency for Medical Research and Development, Naito Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the prognosis of breast cancer has significantly improved compared to other types of cancer, there are still some patients who expire due to recurrence or metastasis. Therefore, it is necessary to develop a method to identify patients with poor prognosis at the early stages of cancer. In the process of discovering new prognostic markers from genes of unknown function, we found that the expression of C1orf50 determines the prognosis of breast cancer patients, especially for those with Luminal A breast cancer. This study aims to elucidate the molecular role of C1orf50 in breast cancer progression. Bioinformatic analyses of the breast cancer dataset of TCGA, and in vitro analyses, reveal the molecular pathways influenced by C1orf50 expression. C1orf50 knockdown suppressed the cell cycle of breast cancer cells and weakened their ability to maintain the undifferentiated state and self-renewal capacity. Interestingly, upregulation of C1orf50 increased sensitivity to CDK4/6 inhibition. In addition, C1orf50 was found to be more abundant in breast cancer cells than in normal breast epithelium, suggesting C1orf50’s involvement in breast cancer pathogenesis. Furthermore, the mRNA expression level of C1orf50 was positively correlated with the expression of PD-L1 and its related factors. These results suggest that C1orf50 promotes breast cancer progression through cell cycle upregulation, maintenance of cancer stemness, and immune evasion mechanisms. Our study uncovers the biological functions of C1orf50 in Luminal breast cancer progression, a finding not previously reported in any type of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorHumansFemalePrognosisDisease ProgressionGene Expression Regulation, NeoplasticCell Line, TumorB7-H1 AntigenCell Proliferation

Stichwörter der Autor:innen

C1orf50Cell cycleImmune evasionLuminal A breast cancerYAP/TAZ

Substanzen

Biomarkers, TumorB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kita-Ku, Okayama, 700-8558, Japan.
  • Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kita-Ku, Okayama, 700-8558, Japan.
  • Department of General Surgery, Kawasaki Medical School General Medical Center, 2-6-1 Nakasange, Kita-Ku, Okayama, 700-8505, Japan.
  • Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kita-Ku, Okayama, 700-8558, Japan. atsushi.fujimura@okayama-u.ac.jp.

Förderung

  • Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan
  • Agency for Medical Research and Development
  • Naito Foundation
  • Okayama University

Zitieren

APA

Otani, Y., Tanaka, A., Maekawa, M., Peña, T., Rogachevskaya, A., Ando, T., Itano, T., Katayama, H., Nakata, E., Ozaki, T., Toyooka, S., Doihara, H., Roehrl, M. H., & Fujimura, A. (2025). The role of C1orf50 in breast cancer progression and prognosis. Breast Cancer. https://doi.org/10.1007/s12282-024-01653-8

Vancouver

Otani Y, Tanaka A, Maekawa M, Peña T, Rogachevskaya A, Ando T, et al. The role of C1orf50 in breast cancer progression and prognosis. Breast Cancer. 2025. doi:10.1007/s12282-024-01653-8

BibTeX
@article{Otani2025,
  author = {Otani, Yusuke and Tanaka, Atsushi and Maekawa, Masaki and Peña, Tirso and Rogachevskaya, Anna and Ando, Teruhiko and Itano, Takuto and Katayama, Haruyoshi and Nakata, Eiji and Ozaki, Toshifumi and Toyooka, Shinichi and Doihara, Hiroyoshi and Roehrl, Michael H and Fujimura, Atsushi},
  title = {The role of C1orf50 in breast cancer progression and prognosis},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-024-01653-8}
}
Kostenlos starten →